NCT00047840

This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.

A Randomized, Double-blind, Multicenter, Phase II Study to Assess the Safety, Tolerability, and Efficacy of ZD6474 in Combination With Docetaxel (TAXOTERE™) in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-based Chemotherapy.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 129 (planned)
• Sponsor: Genzyme, a Sanofi Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the efficacy and safety of ZD6474 in patients with NSCLC after Failure of Prior Platinum-based Chemotherapy.

Conditions

• Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line

Interventions

Type	Name	Description
DRUG	ZD6474
DRUG	Placebo
DRUG	Docetaxel

Timeline

• Start date: 2002-10-01
• Completion: 2006-09-01
• First posted: 2002-10-24
• Last updated: 2016-08-25

Locations

26 sites across 3 countries: United States, Czechia, Hungary